Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Viking Therapeutics Inc (NASDAQ: VKTX) closed at $36.47 up 5.31% from its previous closing price of $34.63. In other words, the price has increased by $5.31 from its previous closing price. On the day, 3.76 million shares were traded. VKTX stock price reached its highest trading level at $37.19 during the session, while it also had its lowest trading level at $34.15.
Ratios:
For a deeper understanding of Viking Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.34 and its Current Ratio is at 28.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on October 29, 2025, initiated with a Buy rating and assigned the stock a target price of $106.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $104.
On April 08, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $30.Goldman initiated its Neutral rating on April 08, 2025, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 28 ’25 when Mancini Marianna sold 6,185 shares for $35.00 per share. The transaction valued at 216,492 led to the insider holds 382,467 shares of the business.
Rowland Charles A Jr sold 60,000 shares of VKTX for $2,134,278 on Oct 27 ’25. The Director now owns 30,000 shares after completing the transaction at $35.57 per share. On Oct 28 ’25, another insider, Lian Brian, who serves as the President & CEO of the company, sold 38,989 shares for $35.01 each. As a result, the insider received 1,364,923 and left with 2,419,109 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 4122435584 and an Enterprise Value of 3408620544.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.66, which has changed by -0.4970225 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $70.41, while it has fallen to a 52-week low of $18.92. The 50-Day Moving Average of the stock is 21.96%, while the 200-Day Moving Average is calculated to be 24.47%.
Shares Statistics:
For the past three months, VKTX has traded an average of 6.54M shares per day and 4966550 over the past ten days. A total of 112.45M shares are outstanding, with a floating share count of 109.62M. Insiders hold about 3.02% of the company’s shares, while institutions hold 67.04% stake in the company. Shares short for VKTX as of 1760486400 were 25450539 with a Short Ratio of 3.89, compared to 1757894400 on 27010893. Therefore, it implies a Short% of Shares Outstanding of 25450539 and a Short% of Float of 26.979999999999997.
Earnings Estimates
Investors are keenly observing as 14.0 analysts analyze and rate. The current performance of Viking Therapeutics Inc (VKTX) in the stock market.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.76 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$2.23 and -$2.87 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$3.66, with 13.0 analysts recommending between -$3.13 and -$4.83.
